• Home
  • Meet Jason
  • Projects
  • People
  • Publications
  • Gallery of Fun
  • News
  • Lab Alumni
  • Undergrad Teaching
  • Cancer Biology Program
  • More
    • Home
    • Meet Jason
    • Projects
    • People
    • Publications
    • Gallery of Fun
    • News
    • Lab Alumni
    • Undergrad Teaching
    • Cancer Biology Program
  • Home
  • Meet Jason
  • Projects
  • People
  • Publications
  • Gallery of Fun
  • News
  • Lab Alumni
  • Undergrad Teaching
  • Cancer Biology Program

PUBLICATIONS

Elevated type I interferon signaling defines the proliferative advantage of ARF and p53 mutant tumor

Elevated type I interferon signaling defines the proliferative advantage of ARF and p53 mutant tumor

Elevated type I interferon signaling defines the proliferative advantage of ARF and p53 mutant tumor

Mabry A, Kuzmicki CE, O'Brien A, Maggi, LB, Weber JD. Under Review.

https://www.biorxiv.org/content/10.1101/2024.11.11.623046v1

ADAR1 regulates lipid remodeling through MDM2 to dictate ferroptosis sensitivity

Elevated type I interferon signaling defines the proliferative advantage of ARF and p53 mutant tumor

Elevated type I interferon signaling defines the proliferative advantage of ARF and p53 mutant tumor

Kung CP, Terzich ND, Ilagen XG, Prinsen MJ, Kaushal M, Kladney RD, Weber JH, Mabry AR, Torres LS, Bramel ER, Freeman EC, Sabloak T, Cottrell KA, Ryu S, Weber WM, Maggi LB, Shriver LP, Patti GJ, Weber JD. Under Review. https://www.biorxiv.org/content/10.1101/2025.01.16.633410v1

Induction of viral mimicry upon loss of DHX9 and ADAR1 in breast cancer cells

Cottrell KA, Ryu S, Pierce JR, Torres LS, Bohlin HE, Schab AM, Weber JD. Cancer Research Communications. 2024 Apr 4;4(4):986-1003. PMCID: PMC10993856.

https://pubmed.ncbi.nlm.nih.gov/38530197/

Activation of PKR by a short-hairpin RNA

Cottrell KA, Ryu S, Donelick HM, Mai H, Young AA, Pierce JR, Bass BL, Weber JD. Scientific Reports. 2024 Oct 9;14(1):23533. PMCID: PMC11464672.

https://pubmed.ncbi.nlm.nih.gov/39384561/

Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility...

Stromal and therapy-induced macrophage proliferation promotes PDAC progression and susceptibility...

Zuo C, Baer JM, Knolhoff BL, Belle JI, Liu X, Alarcon De La Lastra A, Fu C, Hogg GD, Kingston NL, Breden MA, Dodhiawala PB, Zhou DC, Lander VE, James CA, Ding L, Lim KH, Fields RC, Hawkins WG, Weber JD, Zhao G, DeNardo DG. J Exp Med. 2023 Jun 5;220(6):e20212062. doi: 10.1084/jem.20212062. Epub 2023 Mar 23.PMID: 36951731

https://pubmed.ncbi.nlm.nih.gov/36951731/

It's getting complicated-A fresh look at p53-MDM2-ARF triangle in tumorigenesis and cancer therapy

Kung CP and Weber JD.Front Cell Dev Biol. 2022 Jan 26;10:818744. doi: 10.3389/fcell.2022.818744. eCollection 2022.PMID: 35155432

https://pubmed.ncbi.nlm.nih.gov/35155432/

Evaluation of racial/ethnic differences in treatment and mortality among women with triple-negative

Cho B, Han Y, Lian M, Colditz GA, Weber JD, Ma C, Liu Y. JAMA Oncol. 2021 Jul 1;7(7):1016-1023. doi: 10.1001/jamaoncol.2021.1254.PMID: 33983438

https://pubmed.ncbi.nlm.nih.gov/33983438/

8-azaadenosine and 8-chloroadenosine are not selective inhibitors of ADAR

8-azaadenosine and 8-chloroadenosine are not selective inhibitors of ADAR

Cottrell KA, Torres LS, Dizon MG, Weber JD. Cancer Res Commun. 2021 Nov;1(2):56-64. doi: 10.1158/2767-9764.crc-21-0027.PMID: 35586115

https://pubmed.ncbi.nlm.nih.gov/35586115/

Evaluating the therapeutic potential of ADAR1 inhibition for triple-negative breast cancer

Kung CP, Cottrell KA, Ryu S, Bramel ER, Kladney RD, Bao EA, Freeman EC, Sabloak T, Maggi L Jr, Weber JD.Oncogene. 2021 Jan;40(1):189-202. doi: 10.1038/s41388-020-01515-5. Epub 2020 Oct 27.PMID: 33110236

https://pubmed.ncbi.nlm.nih.gov/33110236/

Upregulation of 5'-terminal oligopyrimidine mRNA translation upon loss of the ARF tumor suppressor

Cottrell KA, Chiou RC, Weber JD. Sci Rep. 2020 Dec 17;10(1):22276. doi: 10.1038/s41598-020-79379-8.PMID: 33335292

https://pubmed.ncbi.nlm.nih.gov/33335292/

Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation

Mitochondrial fusion supports increased oxidative phosphorylation during cell proliferation

Yao CH, Wang R, Wang Y, Kung CP, Weber JD, Patti GJ. Elife. 2019 Jan 29;8:e41351. doi: 10.7554/eLife.41351.PMID: 30694178

https://pubmed.ncbi.nlm.nih.gov/30694178/

Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ

Liu Y, West R, Weber JD, Colditz GA. Cancer. 2019 Sep 15;125(18):3225-3233. doi: 10.1002/cncr.32200. Epub 2019 May 23.PMID: 31120565

https://pubmed.ncbi.nlm.nih.gov/31120565/

DHX33 interacts with AP-2β to regulate Bcl-2 gene expression and promote cancer cell survival

Wang J, Feng W, Yuan Z, Weber JD, Zhang Y. Mol Cell Biol. 2019 Aug 12;39(17):e00017-19. doi: 10.1128/MCB.00017-19. Print 2019 Sep 1.PMID: 31182639

https://pubmed.ncbi.nlm.nih.gov/31182639/

Associations of race and ethnicity with risk of developing invasive breast cancer after lobular...

Associations of race and ethnicity with risk of developing invasive breast cancer after lobular...

Dania V, Liu Y, Ademuyiwa F, Weber JD, Colditz GA. Breast Cancer Res. 2019 Nov 14;21(1):120. doi: 10.1186/s13058-019-1219-8.PMID: 31727116

https://pubmed.ncbi.nlm.nih.gov/31727116/

Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer

Wagner AH, Devarakonda S, Skidmore ZL, Krysiak K, Ramu A, Trani L, Kunisaki J, Masood A, Waqar SN, Spies NC, Morgensztern D, Waligorski J, Ponce J, Fulton RS, Maggi LB Jr, Weber JD, Watson MA, O'Conor CJ, Ritter JH, Olsen RR, Cheng H, Mukhopadhyay A, Can I, Cessna MH, Oliver TG, Mardis ER, Wilson RK, Griffith M, Griffith OL, Govindan R. Nat Commun. 2018 Sep 17;9(1):3787. doi: 10.1038/s41467-018-06162-9.PMID: 30224629

https://pubmed.ncbi.nlm.nih.gov/30224629/

The role of RNA editing in cancer development and metabolic disorders

Kung CP, Maggi LB Jr, Weber JD. Front Endocrinol (Lausanne). 2018 Dec 18;9:762. doi: 10.3389/fendo.2018.00762. eCollection 2018.PMID: 30619092

https://pubmed.ncbi.nlm.nih.gov/30619092/

Sabotaging of the oxidative stress response by an oncogenic noncoding RNA

Sabotaging of the oxidative stress response by an oncogenic noncoding RNA

Dania V, Liu Y, Ademuyiwa F, Weber JD, Colditz GA. Breast Cancer Res. 2019 Nov 14;21(1):120. doi: 10.1186/s13058-019-1219-8.PMID: 31727116

https://pubmed.ncbi.nlm.nih.gov/31727116/

2016

DHX33 Transcriptionally Controls Genes Involved in the Cell Cycle.

Yuan B, Wang X, Fan C, You J, Liu Y, Weber JD, Zhong H, Zhang Y.Mol Cell Biol. 2016 Nov 14;36(23):2903-2917. doi: 10.1128/MCB.00314-16. Print 2016 Dec 1.PMID: 27601587

https://pubmed.ncbi.nlm.nih.gov/27601587/

2015

Targeting PTEN-defined breast cancers with a one-two punch.

Maggi LB Jr, Weber JD.Breast Cancer Res. 2015 Apr 8;17(1):51. doi: 10.1186/s13058-015-0566-3.PMID: 25888162

https://pubmed.ncbi.nlm.nih.gov/25888162/


The DHX33 RNA Helicase Promotes mRNA Translation Initiation.

Zhang Y, You J, Wang X, Weber JD.Mol Cell Biol. 2015 Sep 1;35(17):2918-31. doi: 10.1128/MCB.00315-15. Epub 2015 Jun 22.PMID: 26100019

https://pubmed.ncbi.nlm.nih.gov/26100019/

2014

The ARF tumor-suppressor controls Drosha translation to prevent Ras-driven transformation.

Kuchenreuther MJ, Weber JD.Oncogene. 2014 Jan 16;33(3):300-7. doi: 10.1038/onc.2012.601. Epub 2013 Jan 14.PMID: 23318441

https://pubmed.ncbi.nlm.nih.gov/23318441/


ARF tumor suppression in the nucleolus.

Maggi LB Jr, Winkeler CL, Miceli AP, Apicelli AJ, Brady SN, Kuchenreuther MJ, Weber JD.Biochim Biophys Acta. 2014 Jun;1842(6):831-9. doi: 10.1016/j.bbadis.2014.01.016. Epub 2014 Feb 10.PMID: 24525025

https://pubmed.ncbi.nlm.nih.gov/24525025/


ARF and p53 coordinate tumor suppression of an oncogenic IFN-β-STAT1-ISG15 signaling axis.

Forys JT, Kuzmicki CE, Saporita AJ, Winkeler CL, Maggi LB Jr, Weber JD.Cell Rep. 2014 Apr 24;7(2):514-526. doi: 10.1016/j.celrep.2014.03.026. Epub 2014 Apr 13.PMID: 24726362

https://pubmed.ncbi.nlm.nih.gov/24726362/


Elevated DDX21 regulates c-Jun activity and rRNA processing in human breast cancers.

Zhang Y, Baysac KC, Yee LF, Saporita AJ, Weber JD.Breast Cancer Res. 2014 Sep 28;16(5):449. doi: 10.1186/s13058-014-0449-z.PMID: 25260534

https://pubmed.ncbi.nlm.nih.gov/25260534/


TP53 mutations and lung cancer: not all mutations are created equal.

Govindan R, Weber J.Clin Cancer Res. 2014 Sep 1;20(17):4419-21. doi: 10.1158/1078-0432.CCR-14-0899. Epub 2014 Jun 10.PMID: 24916693

https://pubmed.ncbi.nlm.nih.gov/24916693/

2013

P19ARF and RasV¹² offer opposing regulation of DHX33 translation to dictate tumor cell fate.

Zhang Y, Saporita AJ, Weber JD.Mol Cell Biol. 2013 Apr;33(8):1594-607. doi: 10.1128/MCB.01220-12. Epub 2013 Feb 11.PMID: 23401854

https://pubmed.ncbi.nlm.nih.gov/23401854/


Forget transcription: translation is where the action is.

Maggi LB Jr, Weber JD.Mol Cell Biol. 2013 May;33(10):1884-5. doi: 10.1128/MCB.00231-13. Epub 2013 Mar 18.PMID: 23508101

https://pubmed.ncbi.nlm.nih.gov/23508101/


Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.

Zhong H, Sanchez C, Spitzer D, Plambeck-Suess S, Gibbs J, Hawkins WG, Denardo D, Gao F, Pufahl RA, Lockhart AC, Xu M, Linehan D, Weber J, Wang-Gillam A.PLoS One. 2013 Oct 9;8(10):e77243. doi: 10.1371/journal.pone.0077243. eCollection 2013.PMID: 24130864

https://pubmed.ncbi.nlm.nih.gov/24130864/


Posttranscriptional control of T cell effector function by aerobic glycolysis.

Chang CH, Curtis JD, Maggi LB Jr, Faubert B, Villarino AV, O'Sullivan D, Huang SC, van der Windt GJ, Blagih J, Qiu J, Weber JD, Pearce EJ, Jones RG, Pearce EL.Cell. 2013 Jun 6;153(6):1239-51. doi: 10.1016/j.cell.2013.05.016.PMID: 23746840

https://pubmed.ncbi.nlm.nih.gov/23746840/

2012

Hypergrowth mTORC1 signals translationally activate the ARF tumor suppressor checkpoint.

Miceli AP, Saporita AJ, Weber JD.Mol Cell Biol. 2012 Jan;32(2):348-64. doi: 10.1128/MCB.06030-11. Epub 2011 Nov 7.PMID: 22064482

https://pubmed.ncbi.nlm.nih.gov/22064482/


Deconvoluting mTOR biology.

Weber JD, Gutmann DH.Cell Cycle. 2012 Jan 15;11(2):236-48. doi: 10.4161/cc.11.2.19022. Epub 2012 Jan 15.PMID: 22214661

https://pubmed.ncbi.nlm.nih.gov/22214661/


Cathepsin K-Cre causes unexpected germline deletion of genes in mice.

Winkeler CL, Kladney RD, Maggi LB Jr, Weber JD.PLoS One. 2012;7(7):e42005. doi: 10.1371/journal.pone.0042005. Epub 2012 Jul 31.PMID: 22860046

https://pubmed.ncbi.nlm.nih.gov/22860046/

2011

Identification of FUSE-binding protein 1 as a regulatory mRNA-binding protein that represses nucleophosmin translation.

Olanich ME, Moss BL, Piwnica-Worms D, Townsend RR, Weber JD.Oncogene. 2011 Jan 6;30(1):77-86. doi: 10.1038/onc.2010.404. Epub 2010 Aug 30.PMID: 20802533

https://pubmed.ncbi.nlm.nih.gov/20802533/


Identification of DHX33 as a mediator of rRNA synthesis and cell growth.

Zhang Y, Forys JT, Miceli AP, Gwinn AS, Weber JD.Mol Cell Biol. 2011 Dec;31(23):4676-91. doi: 10.1128/MCB.05832-11. Epub 2011 Sep 19.PMID: 21930779

https://pubmed.ncbi.nlm.nih.gov/21930779/


RNA helicase DDX5 is a p53-independent target of ARF that participates in ribosome biogenesis.

Saporita AJ, Chang HC, Winkeler CL, Apicelli AJ, Kladney RD, Wang J, Townsend RR, Michel LS, Weber JD.Cancer Res. 2011 Nov 1;71(21):6708-17. doi: 10.1158/0008-5472.CAN-11-1472. Epub 2011 Sep 21.PMID: 21937682

https://pubmed.ncbi.nlm.nih.gov/21937682/


Loss of Trop2 promotes carcinogenesis and features of epithelial to mesenchymal transition in squamous cell carcinoma.

Wang J, Zhang K, Grabowska D, Li A, Dong Y, Day R, Humphrey P, Lewis J, Kladney RD, Arbeit JM, Weber JD, Chung CH, Michel LS.Mol Cancer Res. 2011 Dec;9(12):1686-95. doi: 10.1158/1541-7786.MCR-11-0241. Epub 2011 Oct 4.PMID: 21970857

https://pubmed.ncbi.nlm.nih.gov/21970857/

2010

Nucleolar disruption ensures nuclear accumulation of p21 upon DNA damage.

Abella N, Brun S, Calvo M, Tapia O, Weber JD, Berciano MT, Lafarga M, Bachs O, Agell N.Traffic. 2010 Jun;11(6):743-55. doi: 10.1111/j.1600-0854.2010.01063.x. Epub 2010 Mar 19.PMID: 20331843

https://pubmed.ncbi.nlm.nih.gov/20331843/


Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer.

Dong Y, Li A, Wang J, Weber JD, Michel LS.Cancer Res. 2010 Jul 1;70(13):5465-74. doi: 10.1158/0008-5472.CAN-10-0173. Epub 2010 Jun 22.PMID: 20570903

https://pubmed.ncbi.nlm.nih.gov/20570903/


Tuberous sclerosis complex 1: an epithelial tumor suppressor essential to prevent spontaneous prostate cancer in aged mice.

Kladney RD, Cardiff RD, Kwiatkowski DJ, Chiang GG, Weber JD, Arbeit JM, Lu ZH.Cancer Res. 2010 Nov 1;70(21):8937-47. doi: 10.1158/0008-5472.CAN-10-1646. Epub 2010 Oct 12.PMID: 20940396

https://pubmed.ncbi.nlm.nih.gov/20940396/


The ARF tumor suppressor regulates bone remodeling and osteosarcoma development in mice.

Rauch DA, Hurchla MA, Harding JC, Deng H, Shea LK, Eagleton MC, Niewiesk S, Lairmore MD, Piwnica-Worms D, Rosol TJ, Weber JD, Ratner L, Weilbaecher KN.PLoS One. 2010 Dec 30;5(12):e15755. doi: 10.1371/journal.pone.0015755.PMID: 21209895

https://pubmed.ncbi.nlm.nih.gov/21209895/

2009

PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer.

Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, Snider J, Davies SR, Olson JA Jr, Watson MA, Saporita A, Weber JD, Ellis MJ.Cancer Res. 2009 May 1;69(9):3955-62. doi: 10.1158/0008-5472.CAN-08-4450. Epub 2009 Apr 14.PMID: 19366795

https://pubmed.ncbi.nlm.nih.gov/19366795/


Nucleophosmin protein expression level, but not threonine 198 phosphorylation, is essential in growth and proliferation.

Brady SN, Maggi LB Jr, Winkeler CL, Toso EA, Gwinn AS, Pelletier CL, Weber JD.Oncogene. 2009 Sep 10;28(36):3209-20. doi: 10.1038/onc.2009.178. Epub 2009 Jun 29.PMID: 19561638

https://pubmed.ncbi.nlm.nih.gov/19561638/


Nucleophosmin redistribution following heat shock: a role in heat-induced radiosensitization.

Vanderwaal RP, Maggi LB Jr, Weber JD, Hunt CR, Roti Roti JL.Cancer Res. 2009 Aug 15;69(16):6454-62. doi: 10.1158/0008-5472.CAN-08-4896. Epub 2009 Jul 28.PMID: 19638589

https://pubmed.ncbi.nlm.nih.gov/19638589/

2008

A non-tumor suppressor role for basal p19ARF in maintaining nucleolar structure and function.

Apicelli AJ, Maggi LB Jr, Hirbe AC, Miceli AP, Olanich ME, Schulte-Winkeler CL, Saporita AJ, Kuchenreuther M, Sanchez J, Weilbaecher K, Weber JD.Mol Cell Biol. 2008 Feb;28(3):1068-80. doi: 10.1128/MCB.00484-07. Epub 2007 Dec 10.PMID: 18070929

https://pubmed.ncbi.nlm.nih.gov/18070929/


Nucleophosmin serves as a rate-limiting nuclear export chaperone for the Mammalian ribosome.

Maggi LB Jr, Kuchenruether M, Dadey DY, Schwope RM, Grisendi S, Townsend RR, Pandolfi PP, Weber JD.Mol Cell Biol. 2008 Dec;28(23):7050-65. doi: 10.1128/MCB.01548-07. Epub 2008 Sep 22.PMID: 18809582

https://pubmed.ncbi.nlm.nih.gov/18809582/

2007

TSC1 sets the rate of ribosome export and protein synthesis through nucleophosmin translation.

Pelletier CL, Maggi LB Jr, Brady SN, Scheidenhelm DK, Gutmann DH, Weber JD.Cancer Res. 2007 Feb 15;67(4):1609-17. doi: 10.1158/0008-5472.CAN-06-2875.PMID: 17308101 

https://pubmed.ncbi.nlm.nih.gov/17308101/


c-Fms tyrosine 559 is a major mediator of M-CSF-induced proliferation of primary macrophages.

Takeshita S, Faccio R, Chappel J, Zheng L, Feng X, Weber JD, Teitelbaum SL, Ross FP.J Biol Chem. 2007 Jun 29;282(26):18980-90. doi: 10.1074/jbc.M610938200. Epub 2007 Apr 9.PMID: 17420255

https://pubmed.ncbi.nlm.nih.gov/17420255/


Mammalian target of rapamycin: master regulator of cell growth in the nervous system.

Sandsmark DK, Pelletier C, Weber JD, Gutmann DH.Histol Histopathol. 2007 Aug;22(8):895-903. doi: 10.14670/HH-22.895.PMID: 17503347

https://pubmed.ncbi.nlm.nih.gov/17503347/


Nucleophosmin mediates mammalian target of rapamycin-dependent actin cytoskeleton dynamics and proliferation in neurofibromin-deficient astrocytes.

Sandsmark DK, Zhang H, Hegedus B, Pelletier CL, Weber JD, Gutmann DH.Cancer Res. 2007 May 15;67(10):4790-9. doi: 10.1158/0008-5472.CAN-06-4470.PMID: 17510408

https://pubmed.ncbi.nlm.nih.gov/17510408/


Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1.

Wong S, Weber JD.Biochem J. 2007 Nov 1;407(3):451-60. doi: 10.1042/BJ20070151.PMID: 17620057

https://pubmed.ncbi.nlm.nih.gov/17620057/


Therapeutic targets in the ARF tumor suppressor pathway.

Saporita AJ, Maggi LB Jr, Apicelli AJ, Weber JD.Curr Med Chem. 2007;14(17):1815-27. doi: 10.2174/092986707781058869.PMID: 17627519

https://pubmed.ncbi.nlm.nih.gov/17627519/

2006

A faster migrating variant masquerades as NICD when performing in vitro gamma-secretase assays with bacterially expressed Notch substrates.

Keller PC 2nd, Tomita T, Hayashi I, Chandu D, Weber JD, Cistola DP, Kopan R.Biochemistry. 2006 Apr 25;45(16):5351-8. doi: 10.1021/bi052228a.PMID: 16618124

https://pubmed.ncbi.nlm.nih.gov/16618124/


Nucleophosmin is essential for ribosomal protein L5 nuclear export.

Yu Y, Maggi LB Jr, Brady SN, Apicelli AJ, Dai MS, Lu H, Weber JD.Mol Cell Biol. 2006 May;26(10):3798-809. doi: 10.1128/MCB.26.10.3798-3809.2006.PMID: 16648475

https://pubmed.ncbi.nlm.nih.gov/16648475/


Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex.

Lin DI, Barbash O, Kumar KG, Weber JD, Harper JW, Klein-Szanto AJ, Rustgi A, Fuchs SY, Diehl JA.Mol Cell. 2006 Nov 3;24(3):355-66. doi: 10.1016/j.molcel.2006.09.007.PMID: 17081987

https://pubmed.ncbi.nlm.nih.gov/17081987/

2005

Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.

Dasgupta B, Yi Y, Chen DY, Weber JD, Gutmann DH.Cancer Res. 2005 Apr 1;65(7):2755-60. doi: 10.1158/0008-5472.CAN-04-4058.PMID: 15805275

https://pubmed.ncbi.nlm.nih.gov/15805275/


Cerebrospinal fluid proteomic analysis reveals dysregulation of methionine aminopeptidase-2 expression in human and mouse neurofibromatosis 1-associated glioma.

Dasgupta B, Yi Y, Hegedus B, Weber JD, Gutmann DH.Cancer Res. 2005 Nov 1;65(21):9843-50. doi: 10.1158/0008-5472.CAN-05-1842.PMID: 16267007

https://pubmed.ncbi.nlm.nih.gov/16267007/


Nucleolar adaptation in human cancer.

Maggi LB Jr, Weber JD.Cancer Invest. 2005;23(7):599-608. doi: 10.1080/07357900500283085.PMID: 16305988

https://pubmed.ncbi.nlm.nih.gov/16305988/

2004

ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway.

Brady SN, Yu Y, Maggi LB Jr, Weber JD.Mol Cell Biol. 2004 Nov;24(21):9327-38. doi: 10.1128/MCB.24.21.9327-9338.2004.PMID: 15485902

https://pubmed.ncbi.nlm.nih.gov/15485902/

2003

Renewing the debate over the p53 apoptotic response.

Weber JD, Zambetti GP.Cell Death Differ. 2003 Apr;10(4):409-12. doi: 10.1038/sj.cdd.4401226.PMID: 12719717

https://pubmed.ncbi.nlm.nih.gov/12719717/

2001

Solution structure of the p53 regulatory domain of the p19Arf tumor suppressor protein.

DiGiammarino EL, Filippov I, Weber JD, Bothner B, Kriwacki RW.Biochemistry. 2001 Feb 27;40(8):2379-86. doi: 10.1021/bi0024005.PMID: 11327858

https://pubmed.ncbi.nlm.nih.gov/11327858/


Defining the molecular basis of Arf and Hdm2 interactions.

Bothner B, Lewis WS, DiGiammarino EL, Weber JD, Bothner SJ, Kriwacki RW.J Mol Biol. 2001 Nov 23;314(2):263-77. doi: 10.1006/jmbi.2001.5110.PMID: 11718560

https://pubmed.ncbi.nlm.nih.gov/11718560/

2000

The ARF/p53 pathway.

Sherr CJ, Weber JD.Curr Opin Genet Dev. 2000 Feb;10(1):94-9. doi: 10.1016/s0959-437x(99)00038-6.PMID: 10679383

https://pubmed.ncbi.nlm.nih.gov/10679383/


Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex.

Weber JD, Kuo ML, Bothner B, DiGiammarino EL, Kriwacki RW, Roussel MF, Sherr CJ.Mol Cell Biol. 2000 Apr;20(7):2517-28. doi: 10.1128/MCB.20.7.2517-2528.2000.PMID: 10713175

https://pubmed.ncbi.nlm.nih.gov/10713175/


Oncogenic Ras induces p19ARF and growth arrest in mouse embryo fibroblasts lacking p21Cip1 and p27Kip1 without activating cyclin D-dependent kinases.

Groth A, Weber JD, Willumsen BM, Sherr CJ, Roussel MF.J Biol Chem. 2000 Sep 1;275(35):27473-80. doi: 10.1074/jbc.M003417200.PMID: 10842176

https://pubmed.ncbi.nlm.nih.gov/10842176/


p53-independent functions of the p19(ARF) tumor suppressor.

Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, Sherr CJ, Zambetti GP.Genes Dev. 2000 Sep 15;14(18):2358-65. doi: 10.1101/gad.827300.PMID: 10995391

https://pubmed.ncbi.nlm.nih.gov/10995391/

1999

Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.

Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL.Genes Dev. 1999 Oct 15;13(20):2658-69. doi: 10.1101/gad.13.20.2658.PMID: 10541552

https://pubmed.ncbi.nlm.nih.gov/10541552/


Nucleolar Arf sequesters Mdm2 and activates p53.

Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D.Nat Cell Biol. 1999 May;1(1):20-6. doi: 10.1038/8991.PMID: 10559859

https://pubmed.ncbi.nlm.nih.gov/10559859/

1998

Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.

*Kamijo T, *Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ.Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8292-7. doi: 10.1073/pnas.95.14.8292.PMID: 9653180

https://pubmed.ncbi.nlm.nih.gov/9653180/

1997

Ablation of Go alpha-subunit results in a transformed phenotype and constitutively active phosphatidylcholine-specific phospholipase C.

Cheng J, Weber JD, Baldassare JJ, Raben DM.J Biol Chem. 1997 Jul 11;272(28):17312-9. doi: 10.1074/jbc.272.28.17312.PMID: 9211868

https://pubmed.ncbi.nlm.nih.gov/9211868/


Ablation of Goalpha overrides G1 restriction point control through Ras/ERK/cyclin D1-CDK activities.

Weber JD, Cheng J, Raben DM, Gardner A, Baldassare JJ.J Biol Chem. 1997 Jul 11;272(28):17320-6. doi: 10.1074/jbc.272.28.17320.PMID: 9211869

https://pubmed.ncbi.nlm.nih.gov/9211869/


Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase.

Weber JD, Raben DM, Phillips PJ, Baldassare JJ.Biochem J. 1997 Aug 15;326 ( Pt 1)(Pt 1):61-8. doi: 10.1042/bj3260061.PMID: 9337851

https://pubmed.ncbi.nlm.nih.gov/9337851/


Fibronectin and cytokines increase JNK, ERK, AP-1 activity, and transin gene expression in rat hepatic stellate cells.

Poulos JE, Weber JD, Bellezzo JM, Di Bisceglie AM, Britton RS, Bacon BR, Baldassare JJ.Am J Physiol. 1997 Oct;273(4):G804-11. doi: 10.1152/ajpgi.1997.273.4.G804.PMID: 9357821

https://pubmed.ncbi.nlm.nih.gov/9357821/


Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27.

Weber JD, Hu W, Jefcoat SC Jr, Raben DM, Baldassare JJ.J Biol Chem. 1997 Dec 26;272(52):32966-71. doi: 10.1074/jbc.272.52.32966.PMID: 9407076

https://pubmed.ncbi.nlm.nih.gov/9407076/

1996

IL-5 receptor expression and Ig secretion from murine B lymphocytes requires coordinated signaling by membrane Ig, IL-4, and IL-5.

Weber JD, Isakson PC, Purkerson JM.J Immunol. 1996 Nov 15;157(10):4428-35.PMID: 8906818

https://pubmed.ncbi.nlm.nih.gov/8906818/

Copyright © 2025 Weber Lab - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept